Pliant Therapeutics (PLRX)

• Market cap: $84.7M
• 1 day: -6.12%
• 5 days: -16.36%
• 1 month: 0.00%
• 3 months: -9.21%
• 6 months: -89.62%
• Year to date: -89.61%
• 1 year: -88.47%
• 5 years: -94.63%
• 10 years: -93.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Employees: 171

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2,040% more call options, than puts

Call options by funds: $214K | Put options by funds: $10K

5% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 39

12% less funds holding

Funds holding: 160 [Q4 2024] → 141 (-19) [Q1 2025]

11.88% less ownership

Funds ownership: 106.42% [Q4 2024] → 94.53% (-11.88%) [Q1 2025]

32% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 50

83% less funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 1 (-5) [Q1 2025]

91% less capital invested

Capital invested by funds: $853M [Q4 2024] → $78.5M (-$774M) [Q1 2025]